ICAM-1 in Long COVID

ICAM-1, also described as Intercellular adhesion molecule, is a vascular marker reported as elevated in Long COVID (PASC, Post-Acute Sequelae of COVID-19) when patients are compared with healthy controls. The cited literature links this alteration to endothelial activation. This entry summarises Thomas et al. 2024. Group-level associations like this do not translate into an individual diagnostic cut-off.

↑ ElevatedVascular

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryVascular
Also described asIntercellular adhesion molecule
Compared againstHC (healthy controls)
Associated symptomsEndothelial activation
Test typeBlood test (serum / plasma / whole blood)
SourceThomas et al. 2024 — doi:10.1007/s40291-024-00731-z
Condition atlasLong COVID Biomarker Atlas

Related Vascular markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is ICAM-1 high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher ICAM-1 in Long COVID than in healthy controls. Source: Thomas et al. 2024.

What symptoms is ICAM-1 associated with in Long COVID?

The cited literature associates this marker with Endothelial activation. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures ICAM-1?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal ICAM-1 result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. ICAM-1 findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). ICAM-1 in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/icam-1.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.